Main indications and clinical application scope of avatrombopag (Su Kexin)

Avatrombopag (Avatrombopag) is an oral thrombopoietic receptor (TPO-R) agonist, which can stimulate the proliferation and differentiation of bone marrow megakaryocytes by activating the thrombopoietin receptor, thereby increasing platelet levels. The drug is primarily used to treat thrombocytopenia, especially in patients with liver disease or who need to raise their platelet counts before certain surgeries.

The core indications for avatrombopag include:1) Patients with chronic liver disease and thrombocytopenia (TCP), especially in planned Before undergoing invasive surgery or medical procedures, it is necessary to temporarily increase the platelet count to reduce the risk of bleeding; 2) For thrombocytopenia caused by other causes, it can also be used under the guidance of a doctor to help patients maintain safe platelet levels.

In clinical practice, avatrombopag can be used for perioperative management of patients with cirrhosis, liver cancer and other chronic liver diseases, and can also be used as an adjuvant treatment for thrombocytopenia. Compared with traditional blood transfusion and platelet preparations, avatrombopag has the advantages of convenient oral administration, rapid onset of action, and independence from blood products. It also reduces transfusion-related risks, such as transfusion reactions and viral transmission.

The clinical application of avatrombopag should follow the principle of individualized medication, and the dosage and treatment course should be determined according to the patient's basic platelet level, liver function, and surgical risk. Platelet count needs to be monitored during use to avoid thrombotic events caused by excessive platelets. Doctors also need to develop a safe and effective medication plan based on the patient's overall health status and risk of complications to ensure maximum efficacy and reduce potential risks.

Reference materials:https://www.drugs.com/